These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 16924941

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. ADHD drugs and cardiovascular risk.
    Nissen SE.
    N Engl J Med; 2006 Apr 06; 354(14):1445-8. PubMed ID: 16549404
    [No Abstract] [Full Text] [Related]

  • 26. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR, Skimming JW, Muniz R.
    Clin Pediatr (Phila); 2010 Sep 06; 49(9):840-51. PubMed ID: 20693523
    [Abstract] [Full Text] [Related]

  • 27. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O.
    J Psychopharmacol; 2007 Mar 06; 21(2):216-9. PubMed ID: 17329303
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment.
    Torres AR, Whitney J, Gonzalez-Heydrich J.
    Epilepsy Behav; 2008 Feb 06; 12(2):217-33. PubMed ID: 18065271
    [Abstract] [Full Text] [Related]

  • 30. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.
    J Am Acad Child Adolesc Psychiatry; 2011 Oct 06; 50(10):978-90. PubMed ID: 21961773
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder.
    Poulton A.
    Expert Rev Neurother; 2006 Apr 06; 6(4):551-61. PubMed ID: 16623654
    [Abstract] [Full Text] [Related]

  • 35. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P, Hsu HY, Chiou SS, Chao MC.
    Aust N Z J Psychiatry; 2007 Dec 06; 41(12):998-1004. PubMed ID: 17999272
    [Abstract] [Full Text] [Related]

  • 36. Medications for adolescents with attention-deficit/hyperactivity disorder.
    Soileau EJ.
    Adolesc Med State Art Rev; 2008 Aug 06; 19(2):254-67, viii-ix. PubMed ID: 18822831
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. ADHD drugs and cardiovascular risk.
    Rappley MD, Moore JW, Dokken D.
    N Engl J Med; 2006 May 25; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract] [Full Text] [Related]

  • 39. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I, Ramos-Quiroga JA, Ribasés M, Bosch R, Bielsa A, Ordeig MT, Morell M, Miró R, de Cid R, Estivill X, Casas M, Bayés M, Cormand B, Hervás A.
    Mutat Res; 2009 Jun 18; 666(1-2):44-9. PubMed ID: 19457516
    [Abstract] [Full Text] [Related]

  • 40. [Apropos the National Board and Welfare's report on ADDH: some views on the treatment with central nervous system stimulants].
    Zetterström R.
    Lakartidningen; 2002 Aug 29; 99(35):3435-6. PubMed ID: 12362770
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.